PainReform Ltd. (PRFX)

Develops non-opioid pain management therapies, focusing on reformulating existing drugs for better efficacy and safety.

PRFX Stock Quote

Company Report

PainReform Ltd., a clinical-stage specialty pharmaceutical company headquartered in Tel Aviv, Israel, specializes in developing therapeutics aimed at delivering prolonged post-surgical pain relief. At the forefront of its product development is PRF-110, an innovative viscous clear oil-based solution. This solution is strategically administered directly into the surgical wound, offering localized and extended analgesic effects following surgical procedures.

Currently, PainReform Ltd. is actively advancing PRF-110 through two pivotal Phase 3 clinical trials. These trials specifically target patients undergoing bunionectomy surgery and hernia repair, assessing the efficacy and safety of PRF-110 in these clinical settings. The company's commitment to addressing unmet medical needs underscores its mission to enhance post-operative recovery outcomes through innovative pain management solutions.

Founded in 2007, PainReform Ltd. continues to drive forward with its dedication to advancing therapeutic options in pain management.v. With a strong emphasis on clinical research and development, the company aims to establish PRF-110 as a transformative treatment option in the field of surgical pain relief.

PRFX EPS Chart

PRFX Revenue Chart

Stock Research

PFBC HIFS ORC HES RVT CELC GRYP

PRFX Chart

View interactive chart for PRFX

PRFX Profile

PRFX News

Analyst Ratings